Floatz logo

Setmelanotide

Pseudohypoparathyroidism Type 1A

Explore 1 assets in Pseudohypoparathyroidism Type 1A →
Floatz Rating
CCC53/100
Confidence
Indicative
v0.2
Sponsor
Massachusetts General Hospital
Modality
protein_peptide
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT07496463CT.gov
Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a)
—Not Yet Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Pseudohypoparathyroidism Type 1A

AssetSponsorPhaseRating
Setmelanotide (this asset)Massachusetts General HospitalP2CCC · 53

Other indications for Setmelanotide

IndicationSponsorPhaseRating
Bardet-Biedl Syndrome—P4A · 81
Alstrom Syndrome—P4BBB · 75
Inherited Obesity—P3BBB · 73

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Citation

Floatz Terminal. Setmelanotide in Pseudohypoparathyroidism Type 1A. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/setmelanotide-pseudohypoparathyroidism-type-1a

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →